White blood cell (WBC) >= 2000/uL
White blood cells >= 2000/uL, within 4 weeks of randomization
White blood cell (WBC) >= 3,000/ul
White blood cell (WBC) >= 3,000/uL
White blood cell (WBC) greater than or equal to 3,000/ul
Obtained within 14 days prior to course 1 day 1 (C1D1): White blood cells (WBC) >= 2000/uL
While blood cells 2000/ul or more
White blood cells (WBC) >= 2000/uL
White blood cell (WBC) ? 3.00 K/uL
White blood cell count (WBC) > 2500/uL
White blood cell (WBC) >= 2000/uL
White blood cells (WBC) >= 3,000/uL
White blood cell (WBC) > 3500/ul within four weeks of enrollment
White blood cell (WBC) count >= 3,000/uL
White blood cell (WBC) counts > 2500/uL.
Within 14 days of the first dose of study drug: White blood cells (WBCs) >= 2000/uL
WBC < 2,000 uL
White blood cell count (WBC) >= 2000/uL.
Obtained within 14 days prior to randomization/registration: white blood cell (WBC ) >= 2000/uL
While blood cells 2000/ul or more
White blood cell (WBC) count of > 3000/ul
While blood cells 2000/ul or more
White blood cell (WBC) counts > 2500/uL.
White blood cell (WBC) >= 2,500 cells/uL
Obtained within 14 days of the first study treatment: White blood cell (WBC) count > 2500/uL
Leukocytes (white blood cells [WBCs]) >= 3,000/uL.
White blood cell (WBC) >= 2000/uL within 14 days of registration
Obtained within 21 days prior to randomization/registration: White blood cell (WBC) >= 2000/uL.
Obtained within 14 days of the first study treatment: White blood cell (WBC) count > 2500/uL
White blood cell (WBC) counts > 2500/uL
Obtained within 14 days prior to the first study treatment (cycle 1, day 1): white blood cell (WBC) counts > 2500/uL
STUDY TREATMENT: White blood cells (WBC) >= 2000/ul
White blood cell (WBC) count of >= 3000/ul
Leukocytes (white blood cell [WBC]) >= 3,000/uL
White blood cell count (WBC) >= 2000/uL
White blood cells (WBC) >= 3,000/uL
White blood cell (WBC) >= 2000/uL
White blood cell (WBC) >= 2000/uL, within 30 days before study registration
White blood cells (WBC) >= 2000/uL within 14 days prior to first dose
White blood cells (WBC) >= 2000/uL
White blood cells >= 3000/uL obtained < 4 weeks prior to starting treatment
Obtained within 14 days of randomization: White blood cells (WBCs) >= 2000/uL
Within 14 days prior to the first study treatment (cycle 1, day 1): White blood cell (WBC) counts > 2500/uL
White blood cell (WBC) counts > 2500/uL
Performed within 14 days (+ 3 working days) prior to registration: White blood cell (WBC) > 3,000/ul.
White blood cells (WBC)\t>= 2,000/uL
White blood cell count (WBC) >= 3,000/uL
Total white blood cell (WBC) count >= 3000/uL, within 14 days of study registration (within 30 days for pulmonary and cardiac assessments)
White blood cell (WBC) >= 2500 cells/uL (obtained within 28 days prior to first study treatment)
White blood cell (WBC) counts > 2500/uL within 14 days prior to the first study treatment (cycle 1, day 1)
White blood cells (WBC) >= 2000/uL
White blood cell count (WBC) >= 2000/uL should be obtained within 21 days prior to enrollment
Patients with symptoms/signs of hyperleukocytosis or white blood cells (WBC) > 100,000/uL can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2/dose) prior to enrollment
WBC ?2000/uL
White blood cells (WBC) >= 2000 /uL
White blood cell (WBC) >= 3000/uL
White blood cells (WBC) =< 10,000/uL
The use of hydroxyurea prior to study registration is allowed; patients with symptoms/signs of hyperleukocytosis or white blood cell (WBC) > 100,000/uL can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2/dose) prior to study day 0 enrollment
White blood count (WBC) >= 2000/uL obtained within 14 days prior to randomization/registration
White blood cell counts (WBC) > 2500/uL
Within 14 days prior to study entry: White blood cell (WBC) >= 2000/uL
White blood cell count (WBC) >= 2000/uL
White blood cells (WBC) >= 3,000/uL
White blood cell (WBC) count > 2500/uL
Must be met within 28 days of course 1 day 1 (C1D1): White blood cell (WBC) >= 2,000/ul
White blood cell (WBC) >= 3,000/uL
INCLUSION CRITERIA FOR ADDITIONAL PTCy-MILs INFUSION AT RELAPSE: White blood cell count (WBC) >= 2,000/uL
White blood cells (WBC) >= 2500/uL
White blood cell (WBC) >= 3,000/uL obtained no more than 28 days prior to the start of neoadjuvant endocrine therapy
White blood cells (WBC) is >= 1500/ul
White blood cells (WBC) >= 2000/uL
White blood cells (WBC) >= 2,000/uL
White blood cell (WBC) >= 2,500 cells/uL
White blood cells (WBC) >= 3,000/ul
White blood cell (WBC) >= 2000/uL
White blood count (WBC) > 2,500/uL
White blood cells (WBC) >= 3,000/ul
White blood cell (WBC) >= 2000/uL
White blood cell (WBC) >= 2,000/ul
White blood cells (WBC) >= 3 x 10^3/ul
White blood cells (WBC) >= 3000/ul performed within 60 days of enrollment
The use of hydroxyurea prior to study registration is allowed; patients with symptoms/signs of hyperleukocytosis or white blood cells (WBC) > 100,000/uL can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2/dose) prior to enrollment
Within 14 days prior to the first study treatment (cycle 1, day 1): White blood cell (WBC) counts >= 2500/uL.
Receipt of any anti-cancer therapy within 14 days prior to study entry, with the exception of hydroxyurea; if clinically indicated in order to keep white blood cells (WBC) < 30,000/uL, hydroxyurea may be continued through the first cycle
WBC (white blood cell count) is 2000/ul
White blood cell (WBC) >= 3.0 x 10^3/ul
White blood cell (WBC) less than or equal to 2000/uL
White blood cell (WBC) counts > 2500/uL, obtained within 14 days prior to the first study treatment (cycle 1, day 1)
Total absolute phagocyte count (APC = [%neutrophils + %monocytes) x white blood cells [WBC]) is at least 1000/uL
Performed within 14 days prior to study: White blood count (WBC) > 3,000/ul
White blood cells (WBC) >= 2000/uL
White blood cells 2000/ul or more
White blood cell (WBC) >= 2.0 x 10^3/ul
WBC >= 2.0 x 10^3/ul
White blood cell (WBC) >= 3,000/uL
White blood cells (WBC) >= 3500/uL
White blood cell (WBC) counts > 2500/uL
White blood cells (WBC) >= 3000/uL
White blood cell (WBC) >= 2,500 cells/uL
White blood cells (WBC) >= 3000/uL
White blood cell (WBC) > 3500/ul
White blood cell (WBC) >= 2,000 cells/uL
No exclusion for blood counts; however, at the time of treatment initiation, white blood cell (WBC) should be < 30,000/uL (can be controlled with hydroxyurea)
White blood cell count (WBC) >= 3500/ul
White blood cell (WBC) > 2,000/ul
White blood cell (WBC) greater than or equal to 3,000/ul
White blood cell (WBC) >= 3000/UL
White blood cell (WBC) >= 2000/uL
White blood cell (WBC) count >= 2500/ul, obtained within 14 days prior to initiation of study treatment
White blood cells (WBCs) >= 2000/uL
White blood cell (WBC) >= 2000/uL
The use of hydroxyurea prior to study registration is allowed; patients with symptoms/signs of hyperleukocytosis or white blood cell (WBC) > 100,000/uL can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2/dose) prior to enrollment
White blood cells (WBCs) >= 2000/uL
White blood cell (WBC) count >= 2000/uL
White blood cell (WBC) >= 3000/ul
Prior to cyclophosphamide and T cell infusions: white blood cells (WBC) =< 2000/uL
Within 14 days prior to registration: white blood cells (WBC) >= 2,000/uL
White blood cells (WBC) > 2000/uL
Within 14 days prior to the first study treatment (cycle 1, day 1): White blood cells (WBC) counts > 2500/uL
White blood cells (WBCs) >= 2000/uL
White blood cells (WBC) > 3500/ul
White blood cells (WBC) < 2,000/ul
White blood cell (WBC) count of >= 3000/ul
White blood cell (WBC) > 2,000/ul
White blood cell (WBC) >= 3,000 cells/uL
White blood cells (WBC) >= 2500/uL
White blood cells (WBC) >= 2000/uL
White blood cells (WBC) >= 2000/ul
White blood cell (WBC) >= 3,000/ul
White blood cells (WBC) =< 1000/uL
COHORT A: White blood cells (WBC) >= 2000/uL
COHORT B: WBC >= 2000/uL
Obtained within 14 days prior to the first study treatment (cycle 1, day 1); white blood cell (WBC) counts > 2500/uL
White blood cell (WBC) count of >= 3000/ul
White blood cells (WBC) >= 2000/uL
White blood cell (WBC) >= 3,000/ul
Whole blood cell (WBC) >= 3,000/ul
White blood cells (WBC)\t>= 3000/uL
Obtained within 14 days prior to registration: White blood cells (WBC) >= 3,000/ul
White blood cell (WBC) >= 2000/uL
White blood cells (WBC) >= 2000/uL
White blood cells (WBC): >= 2000/uL (~ 2 x 10^9/L)
White blood cells (WBC) >= 3,000/ul
White blood cells (WBC) > 2.0 K/uL
WBC >= 3,000/ul
White blood cell (WBC) >= 2000/uL
White blood cell (WBC) counts > 2500/uL (obtained within 14 days prior to the first study treatment [course 1, day 1])
Within 14 days prior to enrollment/randomization: White blood cells (WBC) >= 3.0 K/uL
White blood cells (WBC) >= 2.0 x 10^3/uL
White blood cells (WBC) >= 2.0 x 10^3/uL
White blood cell (WBC) > 3000/ul
White blood cell (WBC) > 2000/uL
White blood cell (WBC): >= 2000/uL (~2 x 10^9/L)
White blood count (WBC) of > 2000 ul 3
White blood cell (WBC) >= 3000/uL
White blood cell (WBC) >= 2,000 /uL
White blood cells (WBC) < 50,000/ul at screening
Patients with symptoms/signs of hyperleukocytosis or white blood cell (WBC) > 100,000/uL can be treated with leukapheresis prior to enrollment
WBC >/= 3,000/uL
Patients with symptoms/signs of hyperleukocytosis or white blood cells (WBC) > 100,000/uL can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2/dose) prior to enrollment
White blood cell (WBC) >= 3.0 K/uL
White blood cell (WBC) > 3.0 K/uL
WBC > 3.0 K/uL
White blood cell count (WBC) >= 2,000/uL
White blood cells (WBC) >= 3,000/ul
Total absolute phagocyte count (APC = %neutrophils + %monocytes) X white blood cell (WBC) is at least 1000/uL
White blood cell (WBC) >= 2000/uL
White blood cells (WBC) >= 2000/uL
White blood cell (WBC) >= 3,000/uL
White blood cells (WBC) >= 3,000/uL
Severe leukocytosis (white blood cell count [WBC] >= 20,000 cells /uL)
White blood cells (WBCs) >= 2000/uL, obtained within 14 days of the first dose of study drug
White blood cells (WBCs) < 3.0 K/UL in the past 30 days
White blood cell (WBC) > 2.0 k/uL
White blood cells (WBCs) < 3.0 K/UL in the past 30 days
Leukocytes (white blood cells [WBC]) >= 3,000/uL (>= 2,500/uL for African-American participants)
White blood cell (WBC) >= 2,500/uL
Leukocytes >= 3,000/uL; Note: if leukopenia is idiopathic and no other significant co-morbidities exist patients will not be excluded on the basis of their white blood cell (WBC)
White blood cell count (WBC) >= 3,000/ul
Within 30 days of eligibility confirmation: Leukocytes (white blood cells [WBC]) >= 3,000/uL
Obtained within 28 days prior to registration: White blood cell (WBC) >= 2500 cells/uL
White blood cells >= 3,000/uL
White blood cells (WBC) > 2.0 X 10^3/uL
White blood cell (WBC) < 3000/uL
White blood cell (WBC) >= 3,000/uL, performed within 28 days prior to registration
